AFT Pharmaceuticals’ shares fall as drug fails FDA threshold

AFT Pharmaceuticals managing director Hartley Atkinson still believes Pascomer shows promise. (Image: AFT Pharmaceuticals)

Riley Kennedy

Wed, 27 Jul 2022

AFT Pharmaceuticals’ shares have fallen this morning after the company said a drug it is developing to treat facial angiofibromas (FA) had failed to reach the threshold for US Food and Drug Administration (FDA) registration.The company’s shares declined 3.3% to $3.80 in morning trading, after the pharmaceutical company released the findings of its study of its orphan drug Pascomer, which it said found “statistically significant” benefits. However, it did not reach the threshold on the IGA scale – a five-point...

Subscribe to BusinessDesk

Stay informed on business, government and financial developments across New Zealand.

Deeply researched, twice-edited and fact-checked news
Annual subscribers also receive a complimentary subscription to The Wall Street Journal
Personalised email news alerts, plus gift up to 5 stories a month to non-subscribers

You can cancel anytime with two clicks, an email or a phone call.
Find out more.

We are serious about journalism.

Already a Subscriber ? Sign in here.

Name {{ registerForm.errors.get('name') }}

Email address {{ registerForm.errors.get('email') }}

Phone Number {{ registerForm.errors.get('phone') }}

Job Title {{ registerForm.errors.get('title') }}

Password Minimum password length of 8 characters.
Require at least one upper and lowercase, numeric, and special character. {{ registerForm.errors.get('password') }}

Repeat password {{ registerForm.errors.get('password_confirmation') }}

We had trouble validating your card. It's possible your card provider is preventing us from charging the card. Please contact your card provider or customer support.

Credit Card

Cardholder's name

{{ __(plans[index].name) | capitalize }} {{ plans[index].attributes.old_price | currency }} {{ plans[index].price | currency }}

All subscriptions auto renew but are easy to cancel.

I Accept The Terms Of Service

{{ registerForm.errors.get('terms') }}

Tax: {{ taxAmount(selectedPlan) | currency }}

Total Price Including Tax: {{ priceWithTax(selectedPlan) | currency }} {{ selectedPlan.type == 'user' && spark.chargesUsersPerSeat ? '/ '+ spark.seatName : '' }} {{ selectedPlan.type == 'user' && spark.chargesUsersPerTeam ? '/ '+ __('teams.team') : '' }} / {{ __(selectedPlan.interval) | capitalize }}

Markets

Engine repairs drag on for Air NZ

Another ‘hard‘ year for the national carrier, weak FY26 ahead.

Pattrick Smellie 11:55am

Markets

Rakon power struggle ends: Witten to walk

In an exclusive statement, Brent Robinson reveals a new board will be in place in weeks.

Rebecca Stevenson 9:20am

Rakon power struggle ends: Witten to walk

The Quiz Free

QuiznessDesk, Thursday, Aug 28

Think you're clever enough?

The Quizmaster 9:15am

Sponsored

A two-track approach to cracking NZ’s EV charging puzzle

Z Energy aims to support easing adoption bottlenecks by targeting the distinct needs of habitual and journey EV drivers.

Z Energy

Sponsored

AI efforts risk failure without clear business goals – Spark

It’s time for New Zealand businesses to move beyond AI experiments and start delivering measurable value.

Spark

More Markets

Markets

Engine repairs drag on for Air NZ

Another ‘hard‘ year for the national carrier, weak FY26 ahead.

Pattrick Smellie 11:55am

Markets

Air NZ's FY net profit slides in soft market

Air New Zealand has made a $126 million net profit after tax, down from $146m the year before.The airline stated that its 2025 financial year results reflected a sluggish domestic market, global engine maintenance challenges, and significant cost inflation.Earnings before tax wer...

Staff reporters 10:57am